JP2010502946A - ２型糖尿病を診断および処置するための組成物および方法 - Google Patents

２型糖尿病を診断および処置するための組成物および方法 Download PDF

Info

Publication number
JP2010502946A
JP2010502946A JP2009526587A JP2009526587A JP2010502946A JP 2010502946 A JP2010502946 A JP 2010502946A JP 2009526587 A JP2009526587 A JP 2009526587A JP 2009526587 A JP2009526587 A JP 2009526587A JP 2010502946 A JP2010502946 A JP 2010502946A
Authority
JP
Japan
Prior art keywords
diabetes
subject
type
diabetic condition
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009526587A
Other languages
English (en)
Japanese (ja)
Inventor
コハバ ゲルバー，
リピン リュー，
Original Assignee
アメリカン タイプ カルチャー コレクション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アメリカン タイプ カルチャー コレクション filed Critical アメリカン タイプ カルチャー コレクション
Publication of JP2010502946A publication Critical patent/JP2010502946A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009526587A 2006-09-01 2007-03-28 ２型糖尿病を診断および処置するための組成物および方法 Pending JP2010502946A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84171706P 2006-09-01 2006-09-01
PCT/US2007/007875 WO2008030273A2 (fr) 2006-09-01 2007-03-28 Compositions et procédés pour le diagnostic et le traitement du diabète de type 2

Publications (1)

Publication Number Publication Date
JP2010502946A true JP2010502946A (ja) 2010-01-28

Family

ID=39157723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009526587A Pending JP2010502946A (ja) 2006-09-01 2007-03-28 ２型糖尿病を診断および処置するための組成物および方法

Country Status (6)

Country Link
EP (1) EP2069768A4 (fr)
JP (1) JP2010502946A (fr)
CN (1) CN101563597A (fr)
AU (1) AU2007293465A1 (fr)
CA (1) CA2661332A1 (fr)
WO (1) WO2008030273A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2010011860A1 (fr) 2008-07-23 2010-01-28 Diabetomics, Llc Procédé de détection du pré-diabète et du diabète
WO2010132447A2 (fr) * 2009-05-11 2010-11-18 Diabetomics, Llc Procédés pour détecter un prédiabète et un diabète à l'aide de la glycosylation différentielle de protéines
JP5812701B2 (ja) * 2010-06-23 2015-11-17 アークレイ株式会社 血漿グルコース測定方法
WO2012000058A1 (fr) * 2010-07-02 2012-01-05 Newsouth Innovations Pty Limited Héritage d'un dysfonctionnement métabolique
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
WO2014085365A2 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
WO2015065897A1 (fr) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Modèles de cancer et procédés associés
RU2701434C2 (ru) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Связывающие белки и способы их применения
CN103969234B (zh) * 2014-04-17 2017-02-15 山东东兴汇智生物科技有限公司 一种荧光素酶‑多抗原融合蛋白以及蛋白a琼脂糖‑融合蛋白‑抗体复合物
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
EP3209681A4 (fr) 2014-10-23 2018-10-31 NGM Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation
WO2016073855A1 (fr) * 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
CN106906278A (zh) * 2015-12-22 2017-06-30 复旦大学 预测ii型糖尿病心血管并发症风险的生物标记物及其用途
WO2018039557A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
US11378558B2 (en) * 2018-02-27 2022-07-05 Agency For Science, Technology And Research Methods, apparatus, and computer-readable media for glycopeptide identification
CN108872293A (zh) * 2018-08-10 2018-11-23 厦门大学 一种肝泡型包虫病的代谢组学分析及初步筛查模型的构建方法
CN113539470A (zh) * 2020-04-14 2021-10-22 郑州大学第一附属医院 一种糖尿病肾病及非糖尿病性肾脏疾病鉴别诊断预测模型及构建方法
CN114404589B (zh) * 2021-12-24 2023-06-30 浙江大学 Rnase4作为治疗和/或预防糖尿病的药物靶点的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508137A (ja) * 2001-04-30 2005-03-31 スウィッチ・バイオテック・アクチェンゲゼルシャフト 糖尿病随伴性および／または動脈性難治創傷の治療および／または予防のための、そして薬理学的に活性な物質を同定するための、アルファ１−アンチキモトリプシンポリペプチド類またはそれらをコード化している核酸の使用、または、ａｃｔポリペプチドまたはそれをコード化している核酸を、発現している細胞の使用。
JP2005337952A (ja) * 2004-05-28 2005-12-08 Kanazawa Univ Tlo Inc 生活習慣病予知因子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121255A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
US7285631B2 (en) * 2001-08-10 2007-10-23 Serono Genetics Institute S.A. Human cDNAs and proteins and uses thereof
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用
US9062306B2 (en) * 2003-04-29 2015-06-23 Biocrine Ab Methods for identifying compounds for treating type 1 diabetes
EP1718327B1 (fr) * 2003-06-20 2015-01-07 University of Florida Biomarqueurs permettant de differencier des diabetes de types 1 et 2
EP1615035B1 (fr) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Combinaisons de marqueurs pour détecter le diabete de type 1 et 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508137A (ja) * 2001-04-30 2005-03-31 スウィッチ・バイオテック・アクチェンゲゼルシャフト 糖尿病随伴性および／または動脈性難治創傷の治療および／または予防のための、そして薬理学的に活性な物質を同定するための、アルファ１−アンチキモトリプシンポリペプチド類またはそれらをコード化している核酸の使用、または、ａｃｔポリペプチドまたはそれをコード化している核酸を、発現している細胞の使用。
JP2005337952A (ja) * 2004-05-28 2005-12-08 Kanazawa Univ Tlo Inc 生活習慣病予知因子

Also Published As

Publication number Publication date
AU2007293465A1 (en) 2008-03-13
CA2661332A1 (fr) 2008-03-13
WO2008030273A2 (fr) 2008-03-13
EP2069768A4 (fr) 2010-01-20
EP2069768A2 (fr) 2009-06-17
WO2008030273A3 (fr) 2008-08-28
CN101563597A (zh) 2009-10-21

Similar Documents

Publication Publication Date Title
JP2010502946A (ja) ２型糖尿病を診断および処置するための組成物および方法
JP2010539513A (ja) ２型糖尿病の診断および処置のための組成物および方法
US9551720B2 (en) Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
EP3540440B1 (fr) Procédés et utilisations pour l'évaluation des lésions rénales et du statut rénal
US20100267052A1 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
JP2009511911A (ja) 糖尿病関連マーカおよびその使用
EP2834638B1 (fr) Procédés de diagnostic et de pronostic d'un sepsis
TR201807542T4 (tr) Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler.
JP2019523889A (ja) インスリン様増殖因子結合タンパク質７およびメタロプロテアーゼ２の組織阻害剤を使用する急性腎臓傷害の管理
WO2019099706A1 (fr) Marqueurs pour le diagnostic et le traitement de la stéatohépatite non alcoolique (nash) et de la fibrose hépatique avancée
WO2012068545A1 (fr) Ngal et insuffisance rénale aiguë
JP2021511389A (ja) 脊髄性筋萎縮症を治療する方法
EP2875347A1 (fr) Procédés et compositions pour le diagnostic et le pronostic de la sepsie
US20170269106A1 (en) Circulating pulmonary hypertension biomarker
EP3311164B1 (fr) Méthodes et compositions pour le diagnostic et le pronostic de l'appendicite et la différenciation des causes de la douleur abdominale
EP2882767B1 (fr) Évaluation d'une lésion rénale à l'aide de l'acide hyaluronique
CA2698899A1 (fr) Evaluation d'un risque d'insuffisance cardiaque congestive chez des patients traites ou pouvant etre traites avec un agoniste du recepteur gamma active par les proliferateurs des peroxysomes ou avec un thiazolidinedione

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100203

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120530